SWOT Analysis Reports & Company Profiles

Publications found: 164,030
Sort by:

MITSUBISHI TANABE - Remicade Biosimilar in Japan: Rapid Movements in Competitive Landscape!

US$ 300.00

... than NK - Nichi-ikko (Aprogen/Sanofi-Table 3) is also preparing to launch biosimilar of Remicade by 2014/2015. As Nippon Kayaku...........Remicade in Japan is more used by............2014 NHI Price Revisions More Crucial than Remicade Biosimilar For Remicade! In the next NHI price revision due ...

September 2013 4 pages

Annual Strategy Dossier - 2013-2014 - World's 4 Leading Regional Aircraft Manufacturers - Key Strategies, Plans, SWOT, Trends & Strategic Outlook - Bombardier, Embraer, ATR, Sukhoi

US$ 995.00

... near term, Embraer is projected to grow its market share further to 63% through 2013-2015 as against 54% at the end of 2012. Additionally, Embraer’s order intake through ... Field Analysis and strategic outlook for the industry for 2014. Key Strategies & Plans included in the Report for each OEM: 1. Product ...

September 2013 50 pages

CADILA HEALTHCARE , Lipaglyn Launched in India - Survey suggests quick market acceptance, if priced appropriately

US$ 140.00

... of diabetic dyslipidemia patients not controlled by statin alone. Based on our physician survey / assessment of the drug profile / market analysis, we expect Lipaglyn to garner around INR 650 million in peak sales in India ...

September 2013 2 pages

Annual Industry Dossier - Global Agriculture Equipment Industry - 2013-2014 - Key Trends, Issues & Challenges, SWOT, Force Field Analysis & Strategic Outlook

US$ 355.00

... powerful machinery delivering enhanced efficiency as well as operating economics. The emerging markets, on the other hand, derive a sizeable chunk of their annual GDP from the agriculture sector besides employing a substantial proportion of their workforce (in some developing nations this ratio is 20:80) and ...

September 2013 20 pages

Annual Industry Dossier - Global Armored Vehicle Industry - 2013-2014 - Key Trends, Issues & Challenges, SWOT, Force Field Analyis & Strategic Outlook

US$ 355.00

... through the 2013 to 2017 period as per the President’s latest budget request. The European conditions are not good either with the French annual defense spending too, projected to stay flat at €31.4 billion through 2014-2019 under the military budget law with a cumulative funding deficit of about €5.9 ...

September 2013 20 pages

Annual Industry Dossier - Global Automotive Industry - 2013-2014 - Key Trends, Issues & Challenges, SWOT, Force Field Analysis & Strategic Outlook

US$ 355.00

The global automotive industry landscape has undergone a major transformation since the global economic crisis of 2008 with the complete transformation of Detroit 3 that has led to resurgence of GM & a combined Fiat-Chrysler entity, stronger focus on compact & more fuel efficient vehicles, surge of interest ...

September 2013 20 pages

Annual Industry Dossier - Global Business Aviation Industry - 2013-2014 - Key Trends, Issues & Challenges, SWOT, Force Field Analysis & Strategic Outlook

US$ 355.00

The global business aviation industry has been treading cautiously on the recovery path over the recent years since the global economic meltdown of 2008 registered a 3.4% decline in aircraft deliveries to 672 units as well as a moderate drop in industry billing to $18.9 billion for 2012, amid the difficult & ...

September 2013 20 pages

Annual Industry Dossier - Global Construction Equipment Industry - 2013-2014 - Key Trends, Issues & Challenges, SWOT, Force Field Analysis & Strategic Outlook

US$ 355.00

The global construction equipment industry has been on an uphill trajectory of-late after having been through the roller coaster ride over the years driven by rapid Chinese economic growth that was hitherto unknown to the world & which also saw the shifting of industry dynamics with the emergence & rise of ...

September 2013 20 pages

Annual Industry Dossier - Global Military and Civil Helicopter & Rotorcraft Industry - 2013-2014 - Key Trends, Issues & Challenges, SWOT, Force Field Analysis & Strategic Outlook

US$ 355.00

Helicopters & rotorcrafts has been one of the fastest growing segments in the general aviation industry of-late with a 21% growth registered by it in 2012. The military helicopters segment is being driven by rapidly expanding role of helicopters in the overall force structure of armed forces globally, in ...

September 2013 20 pages

Annual Industry Dossier - Global Regional Aircraft Industry - 2013-2014 - Key Trends, Issues & Challenges, SWOT, Force Field Analyis & Strategic Outlook

US$ 355.00

The global market for regional aircraft, traditionally divided across jets & turboprops and dominated as well as marked by the duopoly of Bombardier & Embraer, has seen significant spurt in activity of-late with the growth in demand for larger jets offering more capacity & lower operating costs which has ...

September 2013 20 pages

Annual Industry Dossier - Global Trucking Industry - 2013-2014 - Key Trends, Issues & Challenges, SWOT, Force Field Analysis & Strategic Outlook

US$ 355.00

... markets, in order, to partially offset the ongoing demand slump in Western Europe & Latin America. Overall, the global truck market is projected to grow at 3%-4% annually over the medium term till 2020 with strong growth prospects over the long-term. Against this backdrop, the report analyzes the global ...

September 2013 20 pages

Annual Industry Dossier - North American Armored Vehicle Industry - 2013-2014 - Key Trends, Issues & Challenges, SWOT, Force Field Analysis & Strategic Outlook

US$ 355.00

... Freedom post 9/11 drove the growth of defense industrial base across North America and especially bolstered growth of armored vehicle manufacturers given ... report would be essential for those having strategic interest in the North American Armored Vehicle Industry/Global defense industry & will be especially ...

September 2013 20 pages

MORPHOSYS (MOR) - MOR103/ MOR202 - Partnering is the Beginning of a New Phase of Growth

US$ 140.00

Alliances with GSK and Celgene in 2013 propelled MorphoSys (MOR) in the limelight. This could well be the inflection point in MorphoSys's evolution into a successful mature ... , please read our report released on September 12, 2013, titled, “MOR103/ MOR202 – Partnering is the Beginning of a New Phase of Growth ”.

September 2013 5 pages

Amgen (AMGN) - Onyx Acquisition + Maturing Pipeline + Biosimilar Opportunity = Better Poised Than Large Pharma!

US$ 140.00

Amgen (AMGN) announced the acquisition of Onyx pharma at $125/sh or $10.4b ($9.7b net of est. Onyx cash) in net cash, strengthening its Oncology/ Hematology drug portfolio ($7b in ...

September 2013 7 pages

Generic Advair - 3 years to go, but which generic companies are better poised?

US$ 140.00

... announced the draft guidance for the development of generic version of GSK’s Asthma / COPD drug – Advair (Fluticasone propionate + Salmeterol Xinafoate). The ... guidelines pave the way for generic companies to launch a substitutable and interchangeable version of Advair in the US market, which should ...

September 2013 3 pages

GSK - FDA Advisory committee positive on Anoro Ellipta - First once daily dual bronchodilator for US COPD patients

US$ 90.00

GSK and Theravance jointly announced that the FDA pulmonary allergy Drugs Advisory Committee recommended in favor of approval (11-2) for the once daily, lower dose ... getting impacted to that extent. The MAA (Europe) for Anoro has already been filed in Europe and expected to receive approval by the end ...

September 2013 2 pages

Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1,2, STELARA, GSK-1605786, Vercirnon, Traficet-EN

US$ 250.00

Takeda received priority review status from US FDA for its late stage candidate Vedolizumab (filed for UC and Crhon’s disease (CD), a4ß7 integrin inhibitor) to treat ulcerative colitis indication. Vedolizumab targets the disease by preventing ...

September 2013 7 pages

SymBio pharma - TREAKISYM’s Label Expansion + Rigosertib’s Potential in MDS market + Cash to In-license More!

US$ 140.00

... gained Japan/Korea rights in 2011. Onconova Therapeutics (ONTX) debut in NASDAQ has been very encouraging and should percolate into SymBio especially ... ... For more detail please read our report on SymBio released on 3rd Sept. 2013, titled, "TREAKISYM’s Label Expansion + Rigosertib’s Potential in MDS market + ...

September 2013 3 pages

Edoxaban - HOTSUKAI VTE STUDY Results at ESC-13- Well differentiated and should carve its niche in VTE patients with PE/Renal impairment

US$ 90.00

... presented positive results from the PhIII HOKUSAI-VTE study on Edoxaban in VTE (Venous thromboembolism) treatment. Edoxaban demonstrated non-inferiority in terms of efficacy ... Pradaxa. Based on this data and subgroup analysis, we believe Edoxaban would be preferred primarily in those patients who present with ...

September 2013 2 pages

Celgene (CELG) - Label Expansion of Marketed Product and Newly Drug launches + Maturing Pipeline = Long Term Gain

US$ 140.00

... Apremilast (PR, Psoriasis, PsA), and label and geographic expansion of marketed products – Revlimid, Vidaza, and ABRAXANE (L, mBC, NSCLC; R – pancreatic cancer, PDUFA: Sept. 21, 2013 ... detail please read our report on Celgene released on 2nd Sept. 2013, titled, "Label Expansion of Marketed Product and Newly Drug ...

September 2013 6 pages

Onconova Therapeutics (ONTX) -Near-Term Catalysts = Upside Still!

US$ 200.00

Onconova Therapeutics (ONTX) debut on NASDAQ (IPO: ... in pts with 2nd-line Higher Risk MDS vs. less than six months offered ... ). Our risk reward analysis indicates that ONTX's lead drug, Estybon (Rigosertib/ ON ... our report on Onconova released on 30th August 2013, titled, "Near-Term Catalysts = Upside Still!"

August 2013 11 pages

Ambit Biosciences (AMBI) - Early Approval of Quizartinib in RR-AML = A Risk Worth Taking

US$ 200.00

... kinase-3 inhibitor for acute myeloid leukemia, AML) from Astellas in 2013 armed AMBI to tap the unmet need in refractory/ relapsed AML (RR AML) and related hematological disorders ... read our report on Ambit released on 30th August 2013, titled, "Early Approval of Quizartinib in RR-AML = A Risk Worth Taking".

August 2013 10 pages

Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics

US$ 2,500.00

... need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity ...

August 2013 37 pages

Amazon, QVC Inc., Sears Holding Corp, Valve Corp. -Company Analysis, SWOT, Marketing Strategy

US$ 750.00

... and return. The biggest player in the United States online retail market is Amazon.com and it is expected to remain a clear leader in the years to come. ... for mobile platforms as well. Renub Research study titled “Amazon, QVC Inc., Sears Holding Corp, Valve Corp. -Company Analysis, SWOT, Marketing Strategy” ...

August 2013 59 pages

Apple Inc., Best Buy Co. Inc., J.C. Penney Corp Inc. and Limited Brands Inc.-Company Analysis, SWOT, Marketing Strategy

US$ 750.00

... report we have analyzed key companies of the United States online retail landscape. Apple Inc. is one of the world's most successful and most recognizable companies. ... 8 Figures studies the United States Online Retail Company namely Apple Inc., Best Buy Co. Inc., J.C. Penney Corp Inc. and Limited Brands Inc. ...

August 2013 47 pages

KYORIN, Flutiform Will Make its Japanese Debut Soon - A game changer for Kyorin!

US$ 200.00

... PAFSC committee recommendation, Flutiform (Fluticasone propionate + formoterol) fixed dose combination is likely to get Japanese approval in September. It will be the third ... MDI (Chart 1) and Symbicort Trubohaler. Key advantage with Flutiform is its faster onset of action which gives rapid relief from ...

August 2013 5 pages

Annual Strategy Dossier - 2013-2014 - North America's 7 Leading Armored Vehicle Manufacturers - Key Strategies, Plans, SWOT, Trends & Strategic Outlook - General Dynamics Land Systems, BAE Systems, Oshkosh Corporation, Navistar Defense, Lockheed Martin, Textron Systems, AM General

US$ 1,295.00

... scenario. Most North American OEMs are working towards implementing an array of strategies and plans aimed at partially offsetting the ongoing spending cuts ... Perspective on the Business & Strategic Outlook for all key players for 2013-2014 Gaining access to Key Industry as well as Market Trends, Insights ...

August 2013 76 pages

Annual Strategy Dossier - 2013-2014 - World's 7 Leading Automotive OEMs - Key Strategies, Plans, SWOT, Trends & Strategic Outlook - GM, Toyota, Ford, Volkswagen, Daimler, BMW & Fiat

US$ 1,295.00

... for global leadership in terms of vehicle sales by 2018. 5. Analysis of Daimler & BMW’s strategies aimed at offsetting the ongoing European market slump by boosting sales ... SWOT Analysis & Strategic Outlook for all key players for 2013-2014 Gaining access to Key Industry as well as Market Trends, Insights & ...

August 2013 65 pages

INCYTE – JAKAFI’s Label Expansion in Ref. Metastatic Pancreatic Cancer = Multi-Billion Potential!

US$ 140.00

... Survival analysis data from the PhII, RECAP trial of Ruxolitinib (L – JAKAFI for MF, oral JAK 1/2 inhibitor, PhII/III in PV/ET, partnered with Novartis ... read our report released o 21st Aug., 2013 on INCY, titled “JAKAFI’s Label Expansion in Ref. Metastatic Pancreatic Cancer = Multi-Billion Potential!”

August 2013 3 pages

TAEKDA, TAK-700 - Unable to demonstrate OS benefit in chemo experienced patients- What to expect in chemo naïve pool and in earlier setting?

US$ 90.00

... interim analysis results from the ELM-PC 5 Phase 3 study of Orteronel (TAK-700) plus prednisone in chemo experienced prostate cancer patients. The interim ... were no major concerns. What to expect in Pre-chemo setting from TAK-700? Might demonstrate OS benefit compared to control arm but difficult to beat ...

August 2013 5 pages

TAK-700 - No competitive edge against Zytiga Generics; while in early setting competition is also heating up! In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed

US$ 800.00

TAK-700 - No competitive edge against Zytiga Generics; while in early setting competition is also heating up! In the recent past, treatment paradigm ... Cancer Table 3: Upcoming Milestones- TAK-700 Table 4: Reported Clinical Data of TAK-700 Table 5 Clinical Data Comparision- TAK-700 vs. Zytiga vs. TOK-001 Table ...

July 2013 14 pages

Biogen Idec – Poised to Grow Beyond MS

US$ 140.00

... detail, please read our report released on July 8, 2013, titled, “Poised to Grow Beyond MS”.

July 2013 7 pages

Annual Strategy Dossier - 2013 - World's 10 Leading Construction Equipment Manufacturers - Key Strategies, Plans, SWOT, Trends & Strategic Outlook - Caterpillar, Komatsu, Volvo, Hitachi, Sany, John Deere, CNH, Sandvik, Terex, Kubota

US$ 1,995.00

... BRIC. 3. Analysis of John Deere’s 2018 Growth Strategy driven by BRIC Expansion & Capabilities Integration. 4. Analysis of Komatsu’s 2013-2016 Mid-Range Strategic Plan ... on the Business & Strategic Outlook for all key players for 2013 Gaining access to Key Industry as well as Market Trends, Insights & Growth ...

June 2013 108 pages

Annual Strategy Dossier - 2013 - World's 10 Leading Wheeled Armoured Vehicle Manufacturers - Key Strategies, Plans, Trends, Force Field Analysis & Strategic Outlook - General Dynamics Land Systems, BAE Systems, Oshkosh Corporation, Navistar Defense, Thales, Rheinmetall Defence, Nexter Systems, Iveco Defense Vehicles, Renault Defense Trucks, Textron Systems

US$ 1,657.00

... The European conditions are not good either with the French annual defense spending too, projected to stay flat at €31.4 billion through 2014- ... present macro-environmental uncertainty & difficult global economic conditions. Key Strategies & Plans included in the Report for each OEM: 1. Product Portfolio ...

June 2013 90 pages

Incyte - Label Expansion + Upcoming Milestones Sufficient Reason to Remain Invested for Long Term!

US$ 140.00

... inhibitor, PhII/III in PV/ET, partnered with Novartis for Ex-US rights) and Incyte’s (INCY) maturing pipeline. PhII data of oral RA drug Barcitinib ( ... please read our report released on June 18, 2013, titled, “Incyte - Label Expansion + Upcoming Milestones Sufficient Reason to Remain Invested for Long Term!”

June 2013 9 pages

AGCO Corporation - H1 2013 - Strategic Snapshot, SWOT Analysis, Strategic Initiatives & Developments, Key Trends & Outlook

US$ 195.00

... have a significant focus as well as emphasis on technological innovations capable of delivering & translating into performance & productivity enhancements. This report on AGCO Corporation also includes an insightful SWOT framework analysis on the company; which is used extensively for an assessment of the ...

June 2013 15 pages

AgustaWestland N.V. - H1 2013 - Strategic Snapshot, SWOT Analysis, Strategic Initiatives & Developments, Key Trends & Outlook

US$ 195.00

This strategic report provides key insights into the strategic business aspects of AgustaWestland N.V. based on a holistic assessment as well as comprehensive analysis of business structure, performance, strategies, plans, initiatives & outlook against the backdrop of an evolving industry landscape & shifting ...

June 2013 15 pages

BAE Systems plc - Land & Armaments - H1 2013 - Strategic Snapshot, SWOT Analysis, Strategic Initiatives & Developments, Key Trends & Outlook

US$ 195.00

This strategic report provides key insights into the strategic business aspects of BAE Systems PLC - Land & Armaments, based on a holistic assessment as well as comprehensive analysis of business structure, performance, strategies, plans, initiatives & outlook against the backdrop of an evolving industry ...

June 2013 15 pages

Bell Helicopter - H1 2013 - Strategic Snapshot, SWOT Analysis, Strategic Initiatives & Developments, Key Trends & Outlook

US$ 195.00

This strategic report provides key insights into the strategic business aspects of Bell Helicopter based on a holistic assessment as well as comprehensive analysis of business structure, performance, strategies, plans, initiatives & outlook against the backdrop of an evolving industry landscape & shifting ...

June 2013 15 pages

Bombardier Inc.- H1 2013 - Strategic Snapshot, SWOT Analysis, Strategic Initiatives & Developments, Key Trends & Outlook

US$ 195.00

This strategic report provides key insights into the strategic business aspects of Bombardier Inc. based on a holistic assessment as well as comprehensive analysis of business structure, performance, strategies, plans, initiatives & outlook against the backdrop of an evolving industry landscape witnessing the ...

June 2013 15 pages

Caterpillar Inc. - H1 2013 - Strategic Snapshot, SWOT Analysis, Strategic Initiatives & Developments, Key Trends & Outlook

US$ 195.00

This strategic report provides key insights into the strategic business aspects of Caterpillar Inc. based on a holistic assessment as well as comprehensive analysis of business structure, performance, strategies, plans, initiatives & outlook against the backdrop of an evolving industry landscape & shifting ...

June 2013 15 pages

Cessna Aircraft Company - H1 2013 - Strategic Snapshot, SWOT Analysis, Strategic Initiatives & Developments, Key Trends & Outlook

US$ 195.00

This strategic report provides key insights into the strategic business aspects of Cessna Aircraft Company based on a holistic assessment as well as comprehensive analysis of business structure, performance, strategies, plans, initiatives & outlook against the backdrop of an evolving industry landscape ...

June 2013 15 pages

CLAAS Group - H1 2013 - Strategic Snapshot, SWOT Analysis, Strategic Initiatives & Developments, Key Trends & Outlook

US$ 195.00

... OEMs have a significant focus as well as emphasis on technological innovations capable of delivering & translating into performance & productivity enhancements. This report on CLAAS Group also includes an insightful SWOT framework analysis on the company; which is used extensively for an assessment of the ...

June 2013 15 pages

CNH Global N.V. - H1 2013 - Strategic Snapshot, SWOT Analysis, Strategic Initiatives & Developments, Key Trends & Outlook

US$ 195.00

This strategic report provides key insights into the strategic business aspects of CNH Global N.V. based on a holistic assessment as well as comprehensive analysis of business structure, performance, strategies, plans, initiatives & outlook against the backdrop of an evolving industry landscape & shifting ...

June 2013 15 pages

Daimler AG - H1 2013 - Strategic Snapshot, SWOT Analysis, Strategic Initiatives & Developments, Key Trends & Outlook

US$ 195.00

This strategic report provides key insights into the strategic business aspects of Daimler AG based on a holistic assessment as well as comprehensive analysis of business structure, performance, strategies, plans, initiatives & outlook against the backdrop of an evolving industry landscape & shifting global ...

June 2013 15 pages

Dassault Aviation - H1 2013 - Strategic Snapshot, SWOT Analysis, Strategic Initiatives & Developments, Key Trends & Outlook

US$ 195.00

This strategic report provides key insights into the strategic business aspects of Dassault Aviation based on a holistic assessment as well as comprehensive analysis of business structure, performance, strategies, plans, initiatives & outlook against the backdrop of an evolving industry landscape witnessing ...

June 2013 15 pages

EADS N.V. - H1 2013 - Strategic Snapshot, SWOT Analysis, Strategic Initiatives & Developments, Key Trends & Outlook

US$ 195.00

... Identifying & highlighting areas for making potential Strategic Changes, Adjustments & Realignment Gaining a Strategic Perspective on Business & Industry Outlook for 2013 through an insightful Force Field Framework Analysis Gaining access to Key Industry Trends, Issues & Challenges, Risk Factors & ...

June 2013 15 pages

Embraer S.A.- H1 2013 - Strategic Snapshot, SWOT Analysis, Strategic Initiatives & Developments, Key Trends & Outlook

US$ 195.00

This strategic report provides key insights into the strategic business aspects of Embraer S.A. based on a holistic assessment as well as comprehensive analysis of business structure, performance, strategies, plans, initiatives & outlook against the backdrop of an evolving industry landscape witnessing the ...

June 2013 15 pages

Eurocopter SAS - H1 2013 - Strategic Snapshot, SWOT Analysis, Strategic Initiatives & Developments, Key Trends & Outlook

US$ 195.00

This strategic report provides key insights into the strategic business aspects of Eurocopter SAS based on a holistic assessment as well as comprehensive analysis of business structure, performance, strategies, plans, initiatives & outlook against the backdrop of an evolving industry landscape & shifting ...

June 2013 15 pages

Finmeccanica S.p.A. - H1 2013 - Strategic Snapshot, SWOT Analysis, Strategic Initiatives & Developments, Key Trends & Outlook - H1 2013

US$ 195.00

This strategic report provides key insights into the strategic business aspects of Finmeccanica S.p.A. based on a holistic assessment as well as comprehensive analysis of business structure, performance, strategies, plans, initiatives & outlook against the backdrop of an evolving industry landscape & shifting ...

June 2013 15 pages

Filters

Search

Categories

7,665
6,761
4,993
4,645
4,328
4,036
3,979
3,241
3,083
2,925
2,713
2,595
2,125
2,024
2,008
1,654
1,587
1,254
1,158
1,091
982
791
789
572
494
493
304
1,542
9,254
3,983
67,744
8,589
1,186
3,442

Publishers

53,883
43,113
1,245
3
12
1
5
4
2
2
9
11,951
6
5
12,341
6
3
11,044
12
27
48
6
356
24,220
1
1,042
7
1
1,225
1,830
3
149
352
4
2
2
517
1
60

Regions

171
94
91
91
83
80
54
43
34
32
30
19
18
17
13
12
12
12
11
6
5
5
5
5
4
4
4
4
4
4
3
2
2
2
2
2
2
2
1
470
3
1
1
1
4,304
584
433
18
12
121
9
20
12
1
66
7
1
1,007
32
19
38
40
1
154
20
506
178
28,201
65
240
189
30
630
191
163
299
18
413
48
1,433
634
14
100
23
1,445
1
32
398
1
35
41
322
217
19
23
440
8
1
10
355
671
465
429
3,775
925
8,253
1,134
3
2,843
1,162
4
1
2
3,375
1,390
996
272
798
695
402
2,433
1,099
9,272
120
1,012
4,876
884
503
2
1,712
87
2
167
16
8,662
1,193
80
5,494
313
2,376
707
135
1
4
12
3
42,543
7,541

Price

—

Date

—

Pages

—

Offers